CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [Figure presented]

Medicine & Life Sciences

• Nivolumab 100%
• Everolimus 92%
• Renal Cell Carcinoma 70%
• Health Care Outcome Assessment 48%
• Survival 20%
• Therapeutics 12%
• Standard of Care 10%
• Neoplasm Metastasis 9%
• pazopanib 7%
• Sunitinib 6%
• Survival Analysis 5%
• Neoplasms 5%
• Duration of Therapy 4%
• Proportional Hazards Models 4%
• Interleukin-2 4%
• Sample Size 4%
• Demography 3%
• Odds Ratio 3%
• Databases 3%
• Confidence Intervals 3%
• Bone and Bones 3%
• Safety 3%
• Lung 2%
• Liver 2%
• Mortality 2%
• Incidence 2%